Wells Fargo & Company Rigel Pharmaceuticals Inc Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RIGL
# of Institutions
13Shares Held
355KCall Options Held
0Put Options Held
0-
Telemetry Investments, L.L.C. New York, NY323KShares$4.42 Million0.76% of portfolio
-
Barclays PLC London, X010.6KShares$144,8500.0% of portfolio
-
Bergan Kdv Wealth Management, LLC10KShares$137,0000.0% of portfolio
-
Flagship Harbor Advisors, LLC10KShares$137,0000.0% of portfolio
-
Ifp Advisors, Inc1KShares$13,7000.0% of portfolio
About RIGEL PHARMACEUTICALS INC
- Ticker RIGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 172,836,000
- Market Cap $2.37B
- Description
- Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...